Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

PharmaSGP Holding stock

PSG.DE
DE000A2P4LJ5
A2P4LJ

Price

26.20
Today +/-
+0.20
Today %
+0.77 %

PharmaSGP Holding stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the PharmaSGP Holding stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the PharmaSGP Holding stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the PharmaSGP Holding stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze PharmaSGP Holding's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

PharmaSGP Holding Stock Price History

DatePharmaSGP Holding Price
2/24/202526.20 undefined
2/21/202526.00 undefined
2/20/202526.80 undefined
2/19/202527.00 undefined
2/18/202526.80 undefined
2/17/202527.00 undefined
2/14/202526.40 undefined
2/13/202526.00 undefined
2/12/202525.80 undefined
2/11/202526.80 undefined
2/10/202528.60 undefined
2/7/202528.00 undefined
2/6/202527.80 undefined
2/5/202527.60 undefined
2/4/202527.00 undefined
2/3/202526.80 undefined
1/31/202526.60 undefined
1/30/202526.40 undefined
1/29/202526.00 undefined
1/28/202525.20 undefined
1/27/202526.00 undefined

PharmaSGP Holding Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into PharmaSGP Holding, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by PharmaSGP Holding from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects PharmaSGP Holding’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of PharmaSGP Holding. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into PharmaSGP Holding’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing PharmaSGP Holding’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on PharmaSGP Holding’s growth potential.

PharmaSGP Holding Revenue, EBIT and net profit per share

DatePharmaSGP Holding RevenuePharmaSGP Holding EBITPharmaSGP Holding Net Income
2027e144.4 M undefined45.02 M undefined0 undefined
2026e134.18 M undefined38.73 M undefined25.63 M undefined
2025e124.28 M undefined34.54 M undefined22.18 M undefined
2024e115.49 M undefined31.31 M undefined19.09 M undefined
2023101.1 M undefined24.64 M undefined16.4 M undefined
202285.82 M undefined17.78 M undefined11.95 M undefined
202165.34 M undefined15.8 M undefined10.69 M undefined
202063.25 M undefined14.63 M undefined10.64 M undefined
201962.57 M undefined22.36 M undefined16.71 M undefined
201860.6 M undefined19.55 M undefined14.73 M undefined
201753.06 M undefined15.32 M undefined11.78 M undefined

PharmaSGP Holding Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e
536062636585101115124134144
-13.213.331.613.1730.7718.8213.867.838.067.46
90.5790.0090.3290.4889.2389.4190.1079.1373.3967.9163.19
485456575876910000
111416101011161922250
-27.2714.29-37.50-10.0045.4518.7515.7913.64-
-----------
-----------
12121212121211.990000
-----------
Details

Keystats

Revenue and Growth

The PharmaSGP Holding Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the PharmaSGP Holding is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2017201820192020202120222023
             
73.177.0188.48820.8233.8840.77
5.027.149.199.416.497.768.92
1.682.812.231.680.740.540.49
2.513.272.13.044.19710.12
0.270.140.10.240.292.322.52
82.5890.36102.0922.3732.5351.5162.82
0.190.590.250.750.541.571.18
0000.0602.081.25
00007445390
1.211.081.391.7782.1973.9466.06
0000000
71000000
1.471.671.652.5883.4778.1468.48
84.0592.04103.7424.94116129.65131.3
             
00012121212
00038.1238.1238.1238.12
000-38.61-27.92-21.37-10.85
73.6984.3795.58002.350.77
0000000
73.6984.3795.5811.5122.231.140.04
2.861.430.819.794.528.799.92
00004403650
6.845.626.883.013.025.896.52
660000000
00.260.250.2485.198.068.16
10.367.317.9413.0493.1723.1124.59
00.2500.15073.8865.82
00.110.220.220.271.230.79
0004262166339
00.360.220.40.3375.2766.95
10.367.668.1613.4493.598.3891.55
84.0592.04103.7424.94115.7129.47131.59
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of PharmaSGP Holding provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand PharmaSGP Holding's financial health and stability.

Assets

PharmaSGP Holding's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that PharmaSGP Holding must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of PharmaSGP Holding after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into PharmaSGP Holding's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201720182019202020212022
111416101011
000039
000000
1-604-20
000004
000001,000
472823
14817151224
0000-830
0000-830
000000
000000
000084-4
000000
11-4-5-9584-12
11-4-5-940-1
00000-5
25311-801211
13.858.1517.214.56-71.2223.93
000000

PharmaSGP Holding stock margins

The PharmaSGP Holding margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PharmaSGP Holding. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PharmaSGP Holding.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the PharmaSGP Holding's sales revenue. A higher gross margin percentage indicates that the PharmaSGP Holding retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the PharmaSGP Holding's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the PharmaSGP Holding's total revenue generated. When comparing the revenue margin year over year, investors can gauge the PharmaSGP Holding's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the PharmaSGP Holding. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the PharmaSGP Holding's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

PharmaSGP Holding Margin History

PharmaSGP Holding Gross marginPharmaSGP Holding Profit marginPharmaSGP Holding EBIT marginPharmaSGP Holding Profit margin
2027e90.64 %31.18 %0 %
2026e90.64 %28.87 %19.1 %
2025e90.64 %27.79 %17.85 %
2024e90.64 %27.11 %16.53 %
202390.64 %24.37 %16.22 %
202289.48 %20.71 %13.93 %
202190.07 %24.18 %16.36 %
202090.19 %23.14 %16.82 %
201990.62 %35.74 %26.7 %
201889.27 %32.26 %24.31 %
201791.27 %28.87 %22.21 %

PharmaSGP Holding Stock Sales Revenue, EBIT, Earnings per Share

The PharmaSGP Holding earnings per share therefore indicates how much revenue PharmaSGP Holding has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue PharmaSGP Holding earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates PharmaSGP Holding's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of PharmaSGP Holding’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating PharmaSGP Holding's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

PharmaSGP Holding Revenue, EBIT and net profit per share

DatePharmaSGP Holding Sales per SharePharmaSGP Holding EBIT per sharePharmaSGP Holding Earnings per Share
2027e12.03 undefined0 undefined0 undefined
2026e11.18 undefined0 undefined2.14 undefined
2025e10.36 undefined0 undefined1.85 undefined
2024e9.62 undefined0 undefined1.59 undefined
20238.43 undefined2.05 undefined1.37 undefined
20227.15 undefined1.48 undefined1 undefined
20215.45 undefined1.32 undefined0.89 undefined
20205.27 undefined1.22 undefined0.89 undefined
20195.21 undefined1.86 undefined1.39 undefined
20185.05 undefined1.63 undefined1.23 undefined
20174.42 undefined1.28 undefined0.98 undefined

PharmaSGP Holding business model

PharmaSGP Holding SE is a leading European company specializing in the marketing of over-the-counter and natural pharmaceuticals. The company was founded in 2009 and is headquartered in Gräfelfing near Munich. The history of PharmaSGP began with the vision of founder and CEO Alexander Kurz, who believed that many people were looking for natural alternatives to pharmaceuticals. Kurz founded PharmaSGP with the goal of developing natural health products that help people improve their health and well-being. PharmaSGP's business model focuses on the marketing of over-the-counter and natural pharmaceuticals through pharmacies, drugstores, and online sales. The company has a strong presence in Europe and is also expanding into other regions worldwide. PharmaSGP is divided into three divisions: Consumer Healthcare, Medical Devices, and Healthcare Services. The Consumer Healthcare division offers natural health products and dietary supplements targeting consumers. The company has developed a wide range of products specifically tailored to the needs of people at different stages of life, from pregnancy and breastfeeding to old age. In the field of medical devices, PharmaSGP focuses on the development and marketing of innovative medical devices and technologies tailored to the needs of healthcare professionals. The company has developed a range of medical devices such as medication dispensers or blood glucose meters to facilitate disease treatment. In the Healthcare Services division, the company also offers services such as medical consulting and patient management. This involves holistic patient care, offering various services to ensure effective and comprehensive treatment. PharmaSGP also has an impressive range of products covering various health areas. There are products for dietary supplementation, sleep support, pain therapy, and cold relief, to name just a few. One of PharmaSGP's most well-known products is Yokebe, a natural meal replacement that can help reduce weight. The company is committed to ensuring the quality of its products and therefore works closely with scientists and healthcare professionals to ensure that all products are based on current scientific knowledge and studies. In summary, PharmaSGP is an innovative company focused on the marketing of natural and over-the-counter pharmaceuticals. It has developed a wide range of products and services specifically tailored to the needs of consumers and healthcare professionals. The company is committed to continuously improving the quality of its products and services and works closely with scientists and healthcare professionals to ensure comprehensive patient care. PharmaSGP Holding is one of the most popular companies on Eulerpool.com.

PharmaSGP Holding SWOT Analysis

Strengths

PharmaSGP Holding SE has a strong portfolio of high-quality pharmaceutical products, leading to a competitive advantage in the market.

The company has a strong brand image and reputation for producing reliable and effective medicines.

PharmaSGP Holding SE has a well-established distribution network, ensuring widespread availability of its products.

Weaknesses

The company relies heavily on external suppliers for key ingredients and components, making it vulnerable to supply chain disruptions.

PharmaSGP Holding SE has a limited international presence, which restricts its potential for growth in certain geographical markets.

The company faces regulatory challenges and compliance requirements, which may increase costs and hinder expansion efforts.

Opportunities

There is a growing global demand for pharmaceutical products, presenting an opportunity for PharmaSGP Holding SE to expand its market share.

The company can explore strategic partnerships or acquisitions to enhance its product offerings and enter new markets.

PharmaSGP Holding SE can capitalize on technological advancements in the healthcare industry to develop innovative and more efficient products.

Threats

Increasing competition from both established pharmaceutical companies and emerging players poses a threat to PharmaSGP Holding SE's market position.

Changes in government regulations and healthcare policies may impact the pricing and reimbursement of pharmaceutical products, affecting the company's profitability.

The ongoing COVID-19 pandemic and potential future pandemics can disrupt supply chains and decrease demand for pharmaceutical products.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

PharmaSGP Holding Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

PharmaSGP Holding historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

PharmaSGP Holding shares outstanding

The number of shares was PharmaSGP Holding in 2024 — This indicates how many shares 11.993 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue PharmaSGP Holding earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates PharmaSGP Holding's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of PharmaSGP Holding’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating PharmaSGP Holding's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

PharmaSGP Holding dividend history and estimates

In 2024, PharmaSGP Holding paid a dividend amounting to 1.36 EUR. Dividend means that PharmaSGP Holding distributes a portion of its profits to its owners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

Dividend Overview

The dividend per year chart for PharmaSGP Holding provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify PharmaSGP Holding’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating PharmaSGP Holding's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

PharmaSGP Holding Dividend History

DatePharmaSGP Holding Dividend
2027e0.59 undefined
2026e0.59 undefined
2025e0.59 undefined
2024e0.59 undefined
20230.49 undefined
20220.45 undefined

PharmaSGP Holding dividend payout ratio

In 2024, PharmaSGP Holding had a payout ratio of 45.17%. The payout ratio indicates the percentage of the company's profits that PharmaSGP Holding distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for PharmaSGP Holding represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for PharmaSGP Holding could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate PharmaSGP Holding's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

PharmaSGP Holding Payout Ratio History

DatePharmaSGP Holding Payout ratio
2027e45.17 %
2026e45.17 %
2025e45.17 %
2024e45.17 %
202345.17 %
202245.17 %
202145.17 %
202045.17 %
201945.17 %
201845.17 %
201745.17 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for PharmaSGP Holding.

PharmaSGP Holding latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.47 0.45  (-5.2 %)2024 Q3
12/31/20230.27 0.41  (50.35 %)2023 Q4
9/30/20230.33 0.39  (17.01 %)2023 Q3
6/30/20230.27 0.33  (21.01 %)2023 Q2
12/31/20220.31 0.28  (-10.57 %)2022 Q4
9/30/20220.3 0.33  (8.91 %)2022 Q3
6/30/20220.2 0.25  (23.76 %)2022 Q2
1

PharmaSGP Holding shareholders

%
Name
Stocks
Change
Date
81.40000 % Fischer (Clemens) & Hohlefelder (Madlena)9,768,000012/27/2023
5.38780 % Union Investment Privatfonds GmbH646,53659,8461/2/2024
1.11313 % Berenberg Bank (Asset Management)133,57503/31/2024
0.78413 % Fourton Rahastoyhtiö Oy94,09503/31/2024
0.78413 % Mandatum Asset Management Ltd94,09594,0956/30/2023
0.68093 % Aktia Wealth Management Ltd81,71108/31/2024
0.50833 % Fondita Rahastoyhtiö Oy61,00008/31/2024
0.48001 % Schroder Investment Management Ltd. (SIM)57,60107/31/2024
0.41667 % Principal Verm¿gensverwaltung AG50,00050,0002/29/2024
0 % Keren Finance0-3,2643/31/2023
1
2

PharmaSGP Holding Executives and Management Board

Mr. Michael Rudolf

(49)
PharmaSGP Holding Chief Financial Officer, Member of the Management Board
Compensation 526,000

Ms. Natalie Weigand

(42)
PharmaSGP Holding Chief Executive Officer, Member of the Management Board
Compensation 377,000

Dr. Clemens Fischer

(47)
PharmaSGP Holding Chairman of the Supervisory Board (since 2020)

Ms. Madlena Hohlefelder

(42)
PharmaSGP Holding Deputy Chairman of the Supervisory Board (since 2020)

Dr. Axel Rebien

(52)
PharmaSGP Holding Member of the Supervisory Board
1
2

Most common questions regarding PharmaSGP Holding

What values and corporate philosophy does PharmaSGP Holding represent?

PharmaSGP Holding SE represents values of innovation, quality, and sustainability, as reflected in their corporate philosophy. The company focuses on developing and marketing over-the-counter healthcare and pharmaceutical products. With a strong commitment to health and well-being, PharmaSGP Holding SE strives to provide effective and safe solutions for its customers. Their dedication to research and development ensures the continuous improvement and advancement of their product portfolio. By combining expertise and cutting-edge technologies, PharmaSGP Holding SE aims to contribute to the overall improvement of people's lives.

In which countries and regions is PharmaSGP Holding primarily present?

PharmaSGP Holding SE is primarily present in Germany and Austria.

What significant milestones has the company PharmaSGP Holding achieved?

PharmaSGP Holding SE, a renowned pharmaceutical company, has achieved several significant milestones throughout its successful journey. It has consistently focused on delivering innovative healthcare solutions to its customers, establishing itself as a trusted name in the industry. The company has expanded its market presence by entering into strategic partnerships and collaborations, enabling it to reach a wider customer base. Additionally, PharmaSGP Holding SE has demonstrated remarkable growth by continuously introducing new products and expanding its product portfolio. With its commitment to excellence and dedication to improving overall wellness, PharmaSGP Holding SE has emerged as a leading player in the pharmaceutical sector.

What is the history and background of the company PharmaSGP Holding?

PharmaSGP Holding SE is a prominent pharmaceutical company founded in Germany. With a rich history in the healthcare sector, PharmaSGP has grown steadily over the years. The company primarily focuses on the development, production, and distribution of over-the-counter (OTC) medicines and health products. Backed by extensive research and a team of experts, PharmaSGP aims to improve the well-being of its consumers by offering effective and innovative solutions. With its commitment to quality, safety, and customer satisfaction, PharmaSGP has become a trusted name in the pharmaceutical industry. Their dedication to research and development ensures that they stay at the forefront of providing cutting-edge healthcare products and services.

Who are the main competitors of PharmaSGP Holding in the market?

The main competitors of PharmaSGP Holding SE in the market are other pharmaceutical companies operating in the same industry. Some notable competitors include major players like Bayer AG, Novartis AG, and Roche Holding AG. These companies, like PharmaSGP Holding SE, specialize in the production and distribution of pharmaceutical products. As PharmaSGP Holding SE focuses on the niche market of over-the-counter (OTC) pharmaceuticals, it faces competition from other OTC brands such as Johnson & Johnson, Sanofi, and GlaxoSmithKline. In summary, PharmaSGP Holding SE competes against a diverse range of pharmaceutical companies, both in the OTC market and overall pharmaceutical industry.

In which industries is PharmaSGP Holding primarily active?

PharmaSGP Holding SE is primarily active in the pharmaceutical and healthcare industry.

What is the business model of PharmaSGP Holding?

The business model of PharmaSGP Holding SE revolves around the development, production, and distribution of pharmaceutical and healthcare products. As a leading company in the consumer healthcare sector, PharmaSGP focuses on over-the-counter (OTC) medications, dietary supplements, and medical devices. By leveraging its strong network of partners and extensive marketing expertise, the company strives to provide accessible, high-quality healthcare solutions to its customers. PharmaSGP's product portfolio covers various therapeutic areas, including pain relief, cold and flu, and digestion. Through its commitment to innovation, quality, and customer satisfaction, PharmaSGP Holding SE continuously strives to improve health and well-being globally.

What is the P/E ratio of PharmaSGP Holding 2025?

The PharmaSGP Holding P/E ratio is 14.17.

What is the P/S ratio of PharmaSGP Holding 2025?

The PharmaSGP Holding P/S ratio is 2.53.

What is the Quality Investing of PharmaSGP Holding?

The Quality Investing for PharmaSGP Holding is 6/10.

What is the revenue of PharmaSGP Holding 2025?

The expected PharmaSGP Holding revenue is 124.28 M EUR.

How high is the profit of PharmaSGP Holding 2025?

The expected PharmaSGP Holding profit is 22.18 M EUR.

What is the business model of PharmaSGP Holding

PharmaSGP Holding SE is a leading provider of innovative products in the fields of health, beauty, and well-being. The company's business model is based on the development, manufacture, and marketing of high-quality dietary supplements, medical devices, and cosmetics. The products are organized into various segments, including naturopathy, sports nutrition, and anti-aging. In the field of naturopathy, the company offers a wide range of dietary supplements based on natural ingredients. These include products for stress, sleep disorders, or gastrointestinal problems. The products are developed in close collaboration with experts in medicine and naturopathy and meet the highest quality standards. In the field of sports nutrition, the company offers products specifically tailored to the needs of athletes. These contain high-quality, performance-enhancing ingredients such as amino acids, proteins, or carbohydrates. The range includes products for various applications, such as endurance or strength athletes. In the field of anti-aging, the company offers various products aimed at slowing down biological aging and improving skin structure. These include creams, serums, and capsules with antioxidant ingredients such as vitamin C or OPC. Products for improving hair and nails are also part of the range. In addition, PharmaSGP Holding SE is also active in the field of medical devices. This includes products for pain relief, regulation of blood sugar levels, or support of the immune system. The high quality of the products is also a focus in this area. The products are distributed under various brands such as Biotin, IronMaxx, or Biolectra and are available online as well as in pharmacies and drugstores. The marketing is done through both own distribution channels and partnerships. In addition to selling products, PharmaSGP Holding SE also focuses on the development of new technologies and products. This includes the development of apps and digital health solutions. Overall, the business model of PharmaSGP Holding SE is based on the development and marketing of high-quality products with a focus on naturopathy, sports nutrition, and anti-aging. The company relies on close collaboration with experts, highest quality standards, and innovative technologies.

What is the PharmaSGP Holding dividend?

PharmaSGP Holding pays a dividend of 0.45 EUR distributed over payouts per year.

How often does PharmaSGP Holding pay dividends?

The dividend cannot currently be calculated for PharmaSGP Holding or the company does not pay out a dividend.

What is the PharmaSGP Holding ISIN?

The ISIN of PharmaSGP Holding is DE000A2P4LJ5.

What is the PharmaSGP Holding WKN?

The WKN of PharmaSGP Holding is A2P4LJ.

What is the PharmaSGP Holding ticker?

The ticker of PharmaSGP Holding is PSG.DE.

How much dividend does PharmaSGP Holding pay?

Over the past 12 months, PharmaSGP Holding paid a dividend of 0.49 EUR . This corresponds to a dividend yield of about 1.87 %. For the coming 12 months, PharmaSGP Holding is expected to pay a dividend of 0.59 EUR.

What is the dividend yield of PharmaSGP Holding?

The current dividend yield of PharmaSGP Holding is 1.87 %.

When does PharmaSGP Holding pay dividends?

PharmaSGP Holding pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of PharmaSGP Holding?

PharmaSGP Holding paid dividends every year for the past 0 years.

What is the dividend of PharmaSGP Holding?

For the upcoming 12 months, dividends amounting to 0.59 EUR are expected. This corresponds to a dividend yield of 2.26 %.

In which sector is PharmaSGP Holding located?

PharmaSGP Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von PharmaSGP Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PharmaSGP Holding from 7/1/2024 amounting to 1.36 EUR, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did PharmaSGP Holding pay the last dividend?

The last dividend was paid out on 7/1/2024.

What was the dividend of PharmaSGP Holding in the year 2024?

In the year 2024, PharmaSGP Holding distributed 0.49 EUR as dividends.

In which currency does PharmaSGP Holding pay out the dividend?

The dividends of PharmaSGP Holding are distributed in EUR.

All fundamentals about PharmaSGP Holding

Our stock analysis for PharmaSGP Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PharmaSGP Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.